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Purpose. To compare functional results in two cohorts of patients undergoing epithelium-off pulsed (pl-ACXL) and continuous light
accelerated corneal collagen crosslinking (cl-ACXL)with dextran-free riboflavin solution and high-fluence ultraviolet A irradiation.
Design. It is a prospective, comparative, and interventional clinical study.Methods. 20 patients affected by progressive keratoconus
were enrolled in the study. 10 eyes of 10 patients underwent an epithelium-off pl-ACXL by the KXL UV-A source (Avedro Inc.,
Waltham, MS, USA) with 8 minutes (1 sec. on/1 sec. off) of UV-A exposure at 30mW/cm2 and energy dose of 7.2 J/cm2; 10 eyes
of 10 patients underwent an epithelium-off cl-ACXL at 30mW/cm2 for 4 minutes. Riboflavin 0.1% dextran-free solution was used
for a 10-minutes corneal soaking. Patients underwent clinical examination of uncorrected distance visual acuity and corrected
distance visual acuity (UDVA and CDVA), corneal topography and aberrometry (CSO EyeTop, Florence, Italy), corneal OCT
optical pachymetry (Cirrus OCT, Zeiss Meditec, Jena, Germany), endothelial cells count (I-Conan Non Co Robot), and in vivo
scanning laser confocal microscopy (Heidelberg, Germany) at 1, 3, 6, and 12 months of follow-up. Results. Functional results one
year after cl-ACXL and pl-ACXL demonstrated keratoconus stability in both groups. Functional outcomes were found to be better
in epithelium-off pulsed light accelerated treatment together with showing a deeper stromal penetration. No endothelial damage
was recorded during the follow-up in both groups. Conclusions. The study confirmed that oxygen represents the main driver
of collagen crosslinking reaction. Pulsed light treatment optimized intraoperative oxygen availability improving postoperative
functional outcomes compared with continuous light treatment.
1. Introduction
Riboflavin UV-A induced corneal collagen crosslinking
(CXL) represents a relatively new procedure available for the
conservative treatment of progressive keratoconus [1, 2] and
secondary corneal ectasia [3] due to its capacity in increasing
biomechanical corneal resistance [4, 5] and intrinsic anticol-
lagenase activity [6].Thephysiochemical basis of crosslinking
lies in the photodynamic types I-II reactions [7] induced by
the interaction between 0.1% riboflavin molecules absorbed
in corneal tissue and UV-A rays delivered at 3mW/cm2 for
30 minutes (5.4 J/cm2 energy dose) releasing reactive oxygen
species (ROS) that mediated crosslinks formation between
and within collagen fibers [8, 9].
Conventional epithelium-off crosslinking (CXL) demon-
strated its safety and long-term efficacy in stabilizing pro-
gressive keratoconus and secondary ectasias in different
clinical trials [10–15]. On the other hand the procedure is
time consuming lasting about 1 hour [16]. The Bunsen-
Roscoe law of reciprocity [17–19] theoretically demonstrated
that the photochemical process behind crosslinking depends
on the absorbed UV-A energy and its biological effect
is proportional to the total energy dose delivered in the
tissue [17–19]. According to this concept it is theoretically
possible to deliver the same energy dose ensuring a pro-
portional biological effect by setting different UV-A powers
and exposure times in order to accelerate and shorten the
crosslinking procedure in accelerated crosslinking (A-CXL)
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modality [18–20]. According to photochemical crosslinking
studies based on kinetics model [7] the UV-A illumination
caused a rapid depletion of oxygen in a riboflavin soaked
cornea and turning the UV light off led to replenishment
of the oxygen to its original level within 3 to 4 minutes
[7]. Krueger et al. [21] and Herekar [22] have also observed
a rapid oxygen depletion during corneal crosslinking with
riboflavin and concluded that the reactive oxygen species
(ROS), specifically, singlet oxygen, are the predominant CXL
reaction drivers. Under aerobic conditions, which are present
during the first 10 to 15 seconds of UV-A exposure, sensitized
photooxidation of the substrate (proteoglycan core proteins
[23] and collagen in the corneal matrix) occurs mainly by
its reaction with photochemically generated ROS, such as
singlet molecular oxygen. This is consistent with a type II
photochemical mechanism. After the first 10 to 15 seconds,
oxygen becomes totally depleted and the reaction between
the substrate and riboflavin becomes consistent with a pre-
dominantly type I photochemicalmechanism [7]. Pulsing the
UV light during crosslinking treatment theoretically restarts
the photodynamic type II reaction achieving an additional
oxygen concentration allowing more singlet oxygen release
for crosslinking of collagen molecules. We report a com-
parative clinical study of continuous (cl-ACXL) and pulsed
light (pl-ACXL) accelerated corneal collagen crosslinking
in a series of 20 patients with progressive keratoconus
investigating the functional outcomes at one-year follow-up
and estimating the treatment penetration by means of in vivo
confocal microscopy (IVCM).
2. Methods
After specific informed consent subscription, 20 patients
affected by progressive keratoconus were enrolled in the
study.Theywere divided into 2 treatment groups: 10 eyes of 10
patients (pulsed light treatments), with age between 13 and 26
years (mean: 21.5 years), underwent an epithelium-off pulsed
light accelerated corneal collagen crosslinking (pl-ACXL) by
the KXL I UV-A source (Avedro Inc., Waltham, MS, USA)
with 8 minutes (1 sec. on/1 sec. off) of UV-A exposure at
30mW/cm2 with an energy dose of 7.2 J/cm2; 10 eyes of 10
patients (continuous light treatments), with age between 11
and 24 years (mean: 18,5 years), underwent an epithelium-
off continuous light accelerated corneal collagen crosslinking
(cl-ACXL) with the same instrument, UV-A power setting at
30mW/cm2 for 4 minutes of continuous UV-A light expo-
sure, and energy dose of 7.2 J/cm2. The riboflavin solution
used in both treatment groups was composed of dextran-free
riboflavin 0.1% with hydroxyl, propyl, methyl, and cellulose
(VibeX Rapid, Avedro Inc., Waltham, MS, USA), with 10
minutes of corneal soaking. Treated eyes were dressed by
a soft contact lens bandage for 3 days and medicated with
ciprofloxacin eye drops, diclofenac, and sodium hyaluronate
eye drops 4 times/day.
2.1. Inclusion Criteria. The parameters we considered to
establish keratoconus progression and inclusion criteria for
each group were worsening of UCVA/BSCVA > 0.50 Snellen
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Figure 1: Uncorrected distance visual acuity (UDVA) after con-
tinuous light (blue line) and pulsed light (orange line) accelerated
crosslinking gained +0.5 and +0.9 decimal equivalents, respectively,
at one-year follow-up.
lines, increase of SPH/CYL > 0.50D, increase of topo-
graphic symmetry index SAI/SI >1 D, increase of mean K
reading > 1 D, reduction of the thinnest point at corneal
OCTpachymetry≥10𝜇m, and clear cornea at biomicroscopic
examination. We considered “significant” for the inclusion in
the study the variation of at least 3 of the parameters listed
above (one clinical plus two instrumental).
2.2. Assessment Criteria. Pre- and postoperative examination
included uncorrected distance visual acuity (UDVA), cor-
rected distance visual acuity (CDVA), corneal topography
simulated K average readings (K ave.), apical curvature
(AK), and surface aberrometry (coma aberration) by CSO
EyeTop Topographer (Costruzione Strumenti Oftalmici, Flo-
rence, Italy). In vivo scanning laser confocal microscopy
was performed by the HRT II (Rostock Cornea Module,
Heidelberg, Germany) and anterior segmentOCT analysis by
the Cirrus OCT instrument (Zeiss Meditec, Jena, Germany)
in order to assess treatment penetration. Statistical analysis
was performed using Wilcoxon test. All analyses were done
using SPSS v16.0. A P value ≤ 0.05 was considered to be
statistically significant.
3. Results
UDVA showed a statistically not significant improvement of
+0.5, SD ± 1.2 (𝑃 = 0.65) and +0.9, SD ± 1.1 (𝑃 = 0.10)
decimal equivalents in cl-ACXL and pl-ACXL, respectively,
at one-year follow-up; see Figure 1.
CDVA showed an improvement, even not statistically
significant, in both groups by a mean value of +1.6 SD ± 1.0
(P 0.56) and 1.8 SD ± 1.3 (𝑃 = 0.55) decimal equivalents,
respectively, one year after treatment; see Figure 2.
Topographic simulated K average value demonstrated a
not statistically significant decrease one year after cl-ACXL
by a mean value −0.13 Diopters, SD ± 0.13 (𝑃 = 0.088), while
after cl-ACXL the reduction of K average was found to be
statistically significant by amean value of −1.2 Diopters, SD ±
0.4 (𝑃 = 0.049); see Figure 3.
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Table 1: Summary of the results.
ΔUDVA (de) ΔCDVA (de) Δ𝐾 ave. (D) ΔAK (D) ΔComa (𝜇m)
Continuous light ACXL (cl-ACXL) +0.5 +1.6 −0.13 +0.15 +0.44
Pulsed light ACXL (pl-ACXL) +0.9 +1.8 −1.2 −1.39 +0.02
de: decimal equivalents; UDVA: uncorrected distance visual acuity; CDVA: corrected distance visual acuity; Δ𝐾 ave.: delta simulated𝐾 average reading; ΔAK
(D): delta apical curvature; Δcoma: delta coma aberration.
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Figure 2: Corrected distance visual acuity (CDVA) after continuous
light (blue line) and pulsed light (orange line) accelerated crosslink-
ing gained +1.6 and 1.8 decimal equivalents on average, respectively,
one year after treatment.
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Figure 3: Topographic simulatedK average (K ave.) value after con-
tinuous light (blue line) and pulsed light (orange line) accelerated
crosslinking demonstrated a not statistically significant decrease by
a mean value −0.13 Diopters; the reduction of K average was found
to be statistically significant by a mean value of −1.2 Diopters after
pulsed light accelerated CXL.
Apical curvature value (AK) provided by the topographer
showed a slight not statistically significant increase in cl-
ACXL and a statistically significant decrease in pl-ACXL by
a mean value of +0.15 Diopters, SD ± 0.8 (𝑃 = 0.077), and
−1.39 Diopters, SD ± 0.38 (𝑃 = 0.05), respectively, at one-year
follow-up; see Figure 4.
Coma aberration values showed a statistically not signif-
icant difference one year after treatment by a mean value of
+0.44 𝜇m, SD± 0,41 (P 0.58), in cl-ACXL and +0.02 𝜇m, SD ±
0,02 (0.068), in pl-ACXL; see Figure 5.
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Figure 4: Topographic derived apical curvature value (AK) after
continuous light (blue line) and pulsed light (orange line) acceler-
ated crosslinking showed a statistically significant decrease in pulsed
light accelerated CXL by a mean value −1.39 Diopters at one-year
follow-up; no statistically significant differences were recorded in
AK value after continuous light accelerated CXL.
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Figure 5: Coma values showed a statistically not significant
difference one year after treatment. Continuous light accelerated
crosslinking (blue line) was associated with a slight statistically not
significant change of the coma by a mean value of +0.44 𝜇m, while
pulsed light treatment (orange line) showed a stable value during the
follow-up.
In vivo confocal microscopy (IVCM) after cl-ACXL
showed an uneven demarcation line at mean depth of 160 𝜇m
(range: 150–180𝜇m) that was well visible one month after
treatment. A deeper demarcation line was recorded after
pl-ACXL at a mean depth of 200 𝜇m (range: 190–215 𝜇m)
measured from the epithelial surface. A demarcation line was
detectable at slit lamp examination; see Figures 6 and 7 and
Table 1.
Preoperative mean endothelial cell density was 2450
cells/mm2 (range: 2082 to 3026 cells/mm2) in the cl-ACXL
group and 2672 cells/mm2 (range: 2459–3016 cells/mm2) in
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Figure 6: Depths of average demarcation lines recorded onemonth after continuous light (blue bar) and pulsed light (orange bar) accelerated
crosslinking evaluated by corneal OCT (left), Scheimpflug camera (middle), and in vivo confocal microscopy (right) showing a deeper
penetration of pulsed light treatment (orange bars) by a mean value of 215𝜇m (±20𝜇m) versus a lower penetration of continuous light
treatment (blue bars) by a mean value of 160 𝜇m (±20𝜇m).
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Figure 7: In vivo confocal microscopy (IVCM) after continuous light accelerated crosslinking showed keratocytes apoptosis until 175 𝜇m (up
left (a)), an uneven demarcation line is well detectable with spectral domain corneal OCT showing hyperreflective corneal tissue (up, white
arrow (b)); the demarcation line was also visible at slit lamp onemonth after treatment (up right, white arrow (c)). In vivo confocalmicroscopy
(IVCM) after pulsed light accelerated crosslinking showed keratocytes apoptosis until 200 𝜇m (down left (a)); a deeper demarcation line is
well detectable with spectral domain corneal OCT showing hyperreflective corneal tissue (down, white arrow (b)); the demarcation line was
also visible at slit lamp one month after treatment (down right, white arrow (c)).
the pl-ACXL group. Postoperative endothelial cells count
at 12 months was 2355 cells/mm2 on average (range: 2172–
2950 cells/mm2) in the cl-ACXL group and 2495 cells/mm2
(range: 2400–3125 cells/mm2) in pl-ACXL group.
No adverse events were recorded in both treatment
groups during the follow-up.
4. Discussion
This comparative analysis, even if in a small case series,
demonstrated the efficacy of continuous and pulsed light
accelerated crosslinking in stabilizing keratoconus pro-
gression after one year of follow-up. Pulsed light treat-
ment showed a slightly better functional outcome both in
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uncorrected and in corrected distance visual acuity even if
there is no statistically significant difference between the two
treatment modalities. UCVA was found to be slightly better
in pl-ACXL patients and it may correlate with the statistically
significant improvement of mean K values and reduction
of apical curvature recorded in this cohort of patients.
Conversely, there is no statistically significant difference in
CDVA that improved in both groups at one-year follow-up.
This slight difference could be attributed to the small number
of the eyes included in the study. No adverse events were
recorded in both treatment groups.
Pulsed light treatment showed a deeper apoptotic effect,
meanly at 215 𝜇m of stromal depth (range: 190–235𝜇m),
while continuous light accelerated treatment revealed a pen-
etration of 160 𝜇m on average (range: 150–180𝜇m), both at
confocal and at corneal OCT analysis as shown in Figures 6
and 7.
These findings were found to be slightly better than those
recently reported in the literature [24] probably due to the
higher energy dose used in our treatments (7.2 J/cm2 instead
of 5.4 J/cm2) and pulsed light modality. Indeed, pulsing the
UV-A light inducing an intraoperative oxygen reuptake while
prolonging treatment time at 8 minutes may influence a
deeper penetration of oxidative damage [25].
Accelerated corneal collagen crosslinking with pulsed
and continuous UV-A light illumination reached the anterior
part of the corneal stroma until 200𝜇m of depth. This aspect
assumes a physicochemical relevance because, as reported in
the literature [26], the most important biomechanical effect
related to crosslinking is concentrated in the anterior mid-
stroma. Anyway the penetration of accelerated crosslinking
remains under the value of conventional procedure (300 𝜇m)
at 3mW/cm2 for 30 minutes of UV-A exposure. Actually
we do not know if this factor may negatively influence the
biomechanical stability of keratoconus in a long-term follow-
up. Conventional epithelium-off CXL procedure (riboflavin
0.1% plus dextran 20%, UV-A 3mW/cm2 = 5.4 J/cm2 for
30 minutes) remains the gold standard in the conservative
treatment of early-stage progressive keratoconus particularly
in pediatric patients, even if, in our preliminary experi-
ence, the accelerated crosslinking with epithelium removal
demonstrated its safety for endothelium both in pulsed and
in continuous light treatment modality, shortening the CXL
procedure time under 20 minutes, being well tolerated by
patients. Pulsed light treatment seems slightly more capable
to penetrate deeper in the corneal stroma compared to
continuous light treatment giving better functional outcome
even if in a limited case series. The functional improvement
of accelerated CXL with pulsed energy could be traced
back in an optimization of oxygen availability thanks to the
on/off cycle of oxygen delivery. Anyway both treatments were
found to have a similar efficacy in stabilizing keratoconus
during the follow-up period. Pulsed and continuous light
accelerated crosslinking represents safe evolving crosslinking
procedures in order to achieve keratoconus stabilization in
a short treatment time. The efficacy of these techniques still
needs to be investigated in the mid-long-term follow-up and
in a large cohort of patients.
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